They are NOT. They are using 4.1m cases in US, 7.9m cases in US+EU5+JPN. Those are very high number already, and there is NO way they can all be treated under current GILD pricing. So I think the focus on total addressable cases completely misses the key point of current debate because the problem isn't lack of HCV patients to be treated. Remember, the higher the numbers, both addressable HCV cases and estimated revenues, the more problematic the pricing is!
Market Data 
Markets 
AI
